Oxford vaccine generates immune response in the elderly



[ad_1]

According to two sources close to Oxford University research, consulted by the Financial Times, the coronavirus vaccine generated a robust immune response among older adults, one of the most vulnerable groups.

The British print, additionally, noted that the antidote increased the levels of neutralizing antibodies and T cells in the elderly, whose main purpose is to identify and kill invading pathogens.

Despite these positive results, the English newspaper assured that age is still the main risk factor for COVID-19 because the immune system weakens over timeTherefore, this portion of the population is the one that will most need protection against the virus.

“If you have data that shows that the vaccine generates good immunity in the 55+ age group, and that it includes a good response in people who are much older, I think that’s a promising sign,” said Jonathan Ball, professor of virology. from the University of Nottingham, in this same medium.

Last July, The Lancet magazine published the results of the early phases of clinical trials, which indicated that the treatment was safe and effective to neutralize the coronavirus in young people (between 18 and 50 years old).

The vaccine developed by the University of Oxford, which would be available later this year, is currently being tested in the UK, India, South Africa and Brazil, where a clinical trial volunteer died a week ago.



[ad_2]